Posted by Michael Wonder on 30 May 2022
Illuccix reimbursement milestone and launch updates: pass-through status granted in the U.S.
30 May 2022 - Telix Pharmaceuticals today provides an update on the U.S. and Australian launch and reimbursement status for its prostate cancer imaging agent, Illuccix (kit for preparation of gallium (Ga 68) gozetotide).
Telix's prostate cancer imaging agent Illuccix has been granted transitional pass-through payment status by the U.S. Centers for Medicare and Medicaid Services.
Illuccix is available to order for nationwide delivery to all PET imaging sites in Australia, for patient scheduling from 1 July 2022. The Australian launch of Telix's lead imaging product coincides with the listing of prostate-specific membrane antigen positron emission tomography imaging for patients with prostate cancer on the Medicare Benefits Schedule.
